Dr. Fruchtman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
863 Riverside Dr
Suite 1 Fw
New York, NY 10032Phone+1 201-310-1634Fax+1 212-996-8034- Is this information wrong?
Education & Training
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1981 - 1983
- SUNY Health Science Center at BrooklynResidency, Internal Medicine, 1977 - 1981
- New York Medical CollegeClass of 1977
Certifications & Licensure
- NY State Medical License 1978 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2007
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsRigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 studyShyamala C. Navada, Guillermo Garcia-Manero, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado, Maro Ohanian, Rosmy B. John, Erin P. Demakos, Patrick S. Zbysz...> ;Leukemia Research. 2020 May 12
- 7 citationsProceedings of the fifth international RASopathies symposium: When development and cancer intersectKatherine A. Rauen, Lisa Schoyer, Lisa Schill, Beth Stronach, John G. Albeck, Brage S. Andresen, Hélène Cavé, Michelle Ellis, Steven M Fruchtman, Bruce D. Gelb, Christ...> ;American Journal of Medical Genetics. Part A. 2018 Dec 1
- 33 citationsA phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.Shyamala C. Navada, Steven M. Fruchtman, Rosalie Odchimar-Reissig, Erin P. Demakos, Michael E. Petrone, Patrick S. Zbyszewski, James F. Holland, Lewis R. Silverman> ;Leukemia Research. 2018 Jan 1
- Join now to see all
Abstracts/Posters
- Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial CancerMay 12th, 2023
- Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial CancerMay 11th, 2023
- Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark GelderApril 6th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: